Details for Patent: 9,969,740
✉ Email this page to a colleague
Which drugs does patent 9,969,740 protect, and when does it expire?
Patent 9,969,740 protects UKONIQ and is included in one NDA.
This patent has thirteen patent family members in nine countries.
Summary for Patent: 9,969,740
| Title: | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
| Abstract: | The present invention relates to solid state forms of a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrim- idin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one (TGR-1202). The present invention also relates to methods of preparing the same, pharmaceutical compositions containing them, and methods of treating a PI3K kinase mediated disease or disorder, such as cancer, by administering the same. |
| Inventor(s): | Vakkalanka; Swaroop K. (La Chaux-de-Fonds, CH) |
| Assignee: | RHIZEN PHARMACEUTICALS SA (La Chaux-de-Fonds, CH) |
| Application Number: | 15/313,454 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 9,969,740
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY | ⤷ Sign Up | ||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,969,740
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| India | 2596/CHE/2014 | May 27, 2014 |
| PCT Information | |||
| PCT Filed | May 26, 2015 | PCT Application Number: | PCT/IB2015/053940 |
| PCT Publication Date: | December 03, 2015 | PCT Publication Number: | WO2015/181728 |
International Family Members for US Patent 9,969,740
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015265542 | ⤷ Sign Up | |||
| Canada | 2949932 | ⤷ Sign Up | |||
| China | 106661030 | ⤷ Sign Up | |||
| China | 111635406 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
